From: Pulmonary arterial hypertension associated with interferon therapy: a population-based study
Patient characteristics | Number | Percent |
---|---|---|
Indication for interferon | ||
Multiple sclerosis | 7190 | 35.75 |
Hepatitis C | 12,923 | 64.25 |
Age | ||
20–29 | 1205 | 5.99 |
30–39 | 3154 | 15.68 |
40–49 | 7526 | 37.42 |
50–59 | 7084 | 35.22 |
60–65 | 1144 | 5.69 |
Gender | ||
Male | 9906 | 49.25 |
Female | 10,207 | 50.75 |
Comorbiditya | ||
Hypertension | 3612 | 17.96 |
Other liver diseaseb | 2647 | 13.16 |
Diabetes | 1589 | 7.90 |
Chronic pulmonary disease | 750 | 3.73 |
Sleep apnea | 338 | 1.68 |
Connective tissue disorder | 331 | 1.65 |
Obesity | 294 | 1.46 |
HIV/AIDS | 268 | 1.33 |
Valvular heart disease | 156 | 0.78 |
Congestive heart failure | 86 | 0.43 |
Atrial fibrillation and flutter | 74 | 0.37 |
Congenital heart disease | 8 | 0.04 |
Mean ± STD (Median) | ||
Age | 46.36 ± 9.24 (48.00) | |
Follow-up time, months | 29.49 ± 27.41 (20.00) |